Paul Song,
Chief Medical Officer
Dr. Song oversees Cynvenio’s translational and clinical research programs. Dr. Song was formerly a member of the faculty at Cedars Sinai Medical Center, in the Samuel Oschin Cancer Center department of radiation oncology and biomedical sciences. In addition, he serves as Chief Medical Officer at AT-Gen Co. Ltd, where he oversees all clinical aspects of the company’s NK Vue, an ELISA-based blood test which measures natural killer cell activity. Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University. Dr. Song completed his residency in radiation oncology at the University of Chicago and completed a brachytherapy fellowship at the Institut Gustave Roussy. He also was awarded an ASTRO research fellowship by the American Society of Radiation Oncology for his work in genetic radiotherapy.
|
|
|
